BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?

: Gruber FX, Lundán T, Coll R, Siley A, Mikkola I, Rekvig OP, Knuutila S, Remes K, Gedde-Dahl T, Porkka K, Hjort-Hansen H

: 2012

: Medical Oncology

: 1

: 29

: 1

: 219

: 226

: 8

: 1357-0560

DOI: https://doi.org/10.1007/s12032-010-9781-z